Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Net Resources International

04:30 EST 24th November 2017 | BioPortfolio

Here are the most relevant search results for "Net Resources International" found in our extensive news archives from over 250 global news sources.

More Information about Net Resources International on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Net Resources International for you to read. Along with our medical data and news we also list Net Resources International Clinical Trials, which are updated daily. BioPortfolio also has a large database of Net Resources International Companies for you to search.

Showing News Articles 1–25 of 582 from Net Resources International

Thursday 23rd November 2017

Acorda scraps Parkinson’s candidate Tozadenant after five patient deaths

According to Acorda, seven cases of sepsis have been reported out of a total of 890 patients who have taken...Read More... The post Acorda scraps Parkinson’s candidate Tozadenant after five patient deaths appeared first on Drug Development Technology.

Parkinson’s disease: averting a looming ‘pandemic’

Neurological diseases, which include Alzheimer’s disease (AD), dementia and Parkinson’s disease, are the leading causes of disability worldwide, and are...Read More... The post Parkinson’s disease: averting a looming ‘pandemic’ appeared first on Drug Development Technology.

Wednesday 22nd November 2017

Khondrion reports favourable Phase II results of KH176

Netherlands-based pharmaceutical company Khondrion has reported favourable data from preliminary analysis of the Phase II KHENERGY clinical trial evaluating KH176...Read More... The post Khondrion reports favourable Phase II results of KH176 appeared first on Drug Development Technology.

Catalyst Pharma begins Phase II spinal muscular atrophy trial

Catalyst Pharmaceuticals has started a Phase II proof-of-concept clinical trial of Firdapse (amifampridine phosphate) being evaluated in patients suffering from...Read More... The post Catalyst Pharma begins Phase II spinal muscular atrophy trial appeared first on Drug Development Technology.

ArQule commences dosing in trial for cholangiocarcinoma

US-based biopharmaceutical firm ArQule has started dosing in a registrational clinical trial of derazantinib (ARQ 087) to treat patients with...Read More... The post ArQule commences dosing in trial for cholangiocarcinoma appeared first on Drug Development Technology.

Tuesday 21st November 2017

Abivax starts enrolment in Phase IIa ulcerative colitis trial

Abivax has started patient enrolment in a Phase IIa clinical trial (ABX464-101) of its product candidate ABX464 for the treatment...Read More... The post Abivax starts enrolment in Phase IIa ulcerative colitis trial appeared first on Drug Development Technology.

Nevakar initiates dosing in Phase III myopia trial for children

US-based specialty pharmaceutical firm Nevakar has started dosing patients in a Phase III clinical trial to assess its investigational candidate...Read More... The post Nevakar initiates dosing in Phase III myopia trial for children appeared first on Drug Development Technology.

Daiichi Sankyo begins Phase II trial for gastric cancer

Daiichi Sankyo has initiated the Phase II DESTINY-Gastric01 clinical trial of its investigational antibody drug conjugate (ADC) DS-8201 in patients...Read More... The post Daiichi Sankyo begins Phase II trial for gastric cancer appeared first on Drug Development Technology.

Varubi IV’s second-try FDA approval provides CINV patients with a new option

The treatment of chemotherapy-induced nausea and vomiting (CINV) has improved significantly over the past two decades. The current standard of...Read More... The post Varubi IV’s second-try FDA approval provides CINV patients with a new option appeared first on Drug Development Technology.

Monday 20th November 2017

Roche’s haemophilia A drug meets endpoints in Phase III trial

Roche has reported positive findings from the Phase III HAVEN 3 clinical trial of Hemlibra (emicizumab) conducted in adolescents and...Read More... The post Roche’s haemophilia A drug meets endpoints in Phase III trial appeared first on Drug Development Technology.

Umecrine begins enrolment for Phase IIa hypersomnia trial

Karolinska Development’s Umecrine Cognition has initiated patient enrolment in a Phase IIa clinical trial of its drug candidate GR3027 for...Read More... The post Umecrine begins enrolment for Phase IIa hypersomnia trial appeared first on Drug Development Technology.

Galapagos reports Phase II data of cystic fibrosis drug

Belgium-based biotechnology firm Galapagos has reported positive topline data from the Phase II ALBATROSS clinical trial of GLPG2222 in patients...Read More... The post Galapagos reports Phase II data of cystic fibrosis drug appeared first on Drug Development Technology.

The burden of multiple sclerosis is twice as high in women

Multiple sclerosis (MS) is an autoimmune disease that principally affects the central nervous system by causing nerve sheath damage and...Read More... The post The burden of multiple sclerosis is twice as high in women appeared first on Drug Development Technology.

Sunday 19th November 2017

Aerie Pharma starts Phase II trial for ophthalmic disorders

Aerie Pharmaceuticals has started dosing patients in a Phase II clinical trial being conducted to evaluate netarsudil ophthalmic solution (Rhopressa)....Read More... The post Aerie Pharma starts Phase II trial for ophthalmic disorders appeared first on Drug Development Technology.

Celldex starts Phase II trial for head and neck cancer

Celldex Therapeutics has started patient enrolment in a Phase II clinical trial of CDX-3379 to be evaluated in combination with...Read More... The post Celldex starts Phase II trial for head and neck cancer appeared first on Drug Development Technology.

US’s Seattle Children’s begins immunotherapy trial for leukaemia

Seattle Children’s hospital in the US has started a Phase I chimeric antigen receptor (CAR) T-cell immunotherapy trial (PLAT-05) in...Read More... The post US’s Seattle Children’s begins immunotherapy trial for leukaemia appeared first on Drug Development Technology.

Thursday 16th November 2017

Rafael Pharma launches Phase I pancreatic cancer trial

US-based Rafael Pharmaceuticals has launched a Phase I clinical trial of its drug candidate CPI-613 to be assessed in combination...Read More... The post Rafael Pharma launches Phase I pancreatic cancer trial appeared first on Drug Development Technology.

Sobi enrols first patient in Phase III trial for Still’s disease

Swedish Orphan Biovitrum (Sobi) has started patient enrolment in the Phase III anaSTILLs clinical trial of Kineret (anakinra) for Still’s...Read More... The post Sobi enrols first patient in Phase III trial for Still’s disease appeared first on Drug Development Technology.

M&As this week: Court Square Capital Partners, Quotient Sciences Limited, Jinzi Ham

Court Square Capital Partners has acquired a majority stake in clinical research organisation Celerion Holdings from MTS Health Investors. Both Court...Read More... The post M&As this week: Court Square Capital Partners, Quotient Sciences Limited, Jinzi Ham appeared first on Drug Development Technology.

Deals this week: Alnylam Pharmaceuticals, Myovant Sciences, Denali Therapeutics

Alnylam Pharmaceuticals plans to raise $700m through a public offering of five million shares of its common stock priced at $125...Read More... The post Deals this week: Alnylam Pharmaceuticals, Myovant Sciences, Denali Therapeutics appeared first on Drug Development Technology.

Incyte begins Phase II trial for essential thrombocythemia

Incyte has started dosing patients in a Phase II clinical trial of ruxolitinib (Jakafi) in patients with essential thrombocythemia (ET)...Read More... The post Incyte begins Phase II trial for essential thrombocythemia appeared first on Drug Development Technology.

Abilify MyCite: the first digital pill has been approved

In an effort to seek a novel business model, there has been a significant focus on pharma’s strategies to go...Read More... The post Abilify MyCite: the first digital pill has been approved appeared first on Drug Development Technology.

Japan will have the fastest growing prevalent cases of Alzheimer’s

Alzheimer’s disease (AD) is a subtype of dementia in which the brain cells die, leading to declines in memory and...Read More... The post Japan will have the fastest growing prevalent cases of Alzheimer’s appeared first on Drug Development Technology.

Wednesday 15th November 2017

Promius’s sumatriptan meets primary endpoint for migraine

Dr. Reddy’s Laboratories’ subsidiary Promius Pharma has reported positive results from the clinical trial of its ZEMBRACE SymTouch (sumatriptan injection)...Read More... The post Promius’s sumatriptan meets primary endpoint for migraine appeared first on Drug Development Technology.

TapImmune enrols last subject in Phase II breast cancer trial

US-based immuno-oncology firm TapImmune has completed patient enrolment in a Phase II clinical trial of its vaccine candidate TPIV200 to...Read More... The post TapImmune enrols last subject in Phase II breast cancer trial appeared first on Drug Development Technology.


Quick Search
Advertisement
 

News Quicklinks